The company is developing an epilepsy test based on inflammatory proteins in patient blood that is intended for ruling out patients with seizure-like symptoms.
NEW YORK (GenomeWeb News) – MRIGlobal and Evogen today announced a five-year agreement to develop molecular diagnostic products targeting the in vitro and clinical molecular diagnostic markets.
Evogen, a Lenexa, Kansas-based developer of molecular detection and diagnostic technologies, said this week that it has non-exclusively licensed its PCR probe technology to Focus Diagnostics, a Quest Diagnostics subsidiary.
NEW YORK (GenomeWeb News) – Evogen has granted Focus Diagnostics a license to incorporate Evogen's HyBeacons PCR probe technology into Focus' molecular diagnostic products and services, the firms announced today.
